All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ferric maltol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	5076	33725-54-1

Description:

Molecule	Description
Synonyms: ST10 ST10-021 accrufer ferric maltol feraccru	potential use as an oral therapy for iron deficiency anemia Molecular weight: 431.15 Formula: C18H15FeO9 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 157.80 ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
S (Water solubility)	5.90 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
July 25, 2019	FDA	SHIELD TX UK LTD
Feb. 18, 2016	EMA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B03AB10	BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS IRON PREPARATIONS Iron trivalent, oral preparations
MeSH PA	D006397	Hematinics
MeSH PA	D006401	Hematologic Agents
CHEBI has role	CHEBI:75835	anti-anaemic agent

Related Drugs by ATC class:

B03AB Iron trivalent, oral preparations 4 drugs

chondroitin sulfate-iron complexferric hydroxidesodium feredetatesucroferric oxyhydroxide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Iron deficiency anemia	indication	87522002
Iron overload	contraindication	60737008
Hemochromatosis	contraindication	399187006	DOID:2352

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
30MG IRON	ACCRUFER	SHIELD TX	N212320	July 25, 2019	RX	CAPSULE	ORAL	9248148	March 29, 2031	METHOD OF TREATING IRON DEFICIENCY
30MG IRON	ACCRUFER	SHIELD TX	N212320	July 25, 2019	RX	CAPSULE	ORAL	10179120	Jan. 6, 2035	METHOD OF TREATING IRON DEFICIENCY
30MG IRON	ACCRUFER	SHIELD TX	N212320	July 25, 2019	RX	CAPSULE	ORAL	9802973	Oct. 23, 2035	METHOD OF TREATING IRON DEFICIENCY

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
30MG IRON	ACCRUFER	SHIELD TX	N212320	July 25, 2019	RX	CAPSULE	ORAL	Dec. 19, 2028	NEW PATIENT POPULATION

Bioactivity Summary:

None

External reference:

ID	Source
4044157	VANDF
CHEBI:757527	CHEBI
CHEMBL4298110	ChEMBL_ID
D10833	KEGG_DRUG
C062088	MESH_SUPPLEMENTAL_RECORD_UI
DB15598	DRUGBANK_ID
2539932	RXNORM
31631	MMSL
349513	MMSL
d08432	MMSL
017087	NDDF
C0060237	UMLSCUI
9974	INN_ID
169535	PUBCHEM_CID
MA10QYF1Z0	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ACCRUFER	HUMAN PRESCRIPTION DRUG LABEL	1	73059-001	CAPSULE	30 mg	ORAL	NDA	19 sections